These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 31221512)
1. Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing. Shin DW; Kim SM; Kim JA; Park HS; Hwang SM; Im K; Kim S; Kim J; Kwon S; Yoon SS; Lee DS Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e496-e505. PubMed ID: 31221512 [TBL] [Abstract][Full Text] [Related]
2. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177 [TBL] [Abstract][Full Text] [Related]
3. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994 [TBL] [Abstract][Full Text] [Related]
4. Detection of the MYD88 Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844 [TBL] [Abstract][Full Text] [Related]
5. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055 [TBL] [Abstract][Full Text] [Related]
6. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075 [TBL] [Abstract][Full Text] [Related]
8. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371 [TBL] [Abstract][Full Text] [Related]
9. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664 [TBL] [Abstract][Full Text] [Related]
10. Significances of MYD88 Meng Q; Cao XX; Li J Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839 [TBL] [Abstract][Full Text] [Related]
11. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients]. Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092 [No Abstract] [Full Text] [Related]
12. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930 [No Abstract] [Full Text] [Related]
13. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Xu L; Hunter ZR; Yang G; Zhou Y; Cao Y; Liu X; Morra E; Trojani A; Greco A; Arcaini L; Varettoni M; Brown JR; Tai YT; Anderson KC; Munshi NC; Patterson CJ; Manning RJ; Tripsas CK; Lindeman NI; Treon SP Blood; 2013 Mar; 121(11):2051-8. PubMed ID: 23321251 [TBL] [Abstract][Full Text] [Related]
14. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia. Kim JA; Im K; Park SN; Kwon J; Choi Q; Hwang SM; Sekiguchi N; Yoon SS; Lee DS; Kim SY Biomed Res Int; 2014; 2014():363540. PubMed ID: 24895570 [TBL] [Abstract][Full Text] [Related]
15. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258 [TBL] [Abstract][Full Text] [Related]
16. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Schmidt J; Federmann B; Schindler N; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L Br J Haematol; 2015 Jun; 169(6):795-803. PubMed ID: 25819228 [TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. Moreno DF; López-Guerra M; Paz S; Oliver-Caldés A; Mena MP; Correa JG; Battram AM; Osuna M; Rivas-Delgado A; Rodríguez-Lobato LG; Cardús O; Tovar N; Cibeira MT; Jiménez-Segura R; Bladé J; Rosiñol L; Colomer D; Fernández de Larrea C Br J Haematol; 2023 Jan; 200(2):187-196. PubMed ID: 36210485 [TBL] [Abstract][Full Text] [Related]